Skip to main content
. 2017 Jun 19;13(8):e694–e702. doi: 10.1200/JOP.2016.020206

Fig 3.

Fig 3.

Proportions of prescription claims for abiraterone and enzalutamide among advanced prostate cancer care providers. This figure does not include claims for non-medical oncologist or urologist providers who prescribed > 10 prescriptions for either drug.